Study of YG1699 for people with diabetes and kidney disease
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new medicine called YG1699 to see how it works in people who have both diabetes and kidney disease, including those on dialysis. It may help control blood sugar, but we need to learn more about its effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have type 1 or type 2 diabetes with kidney problems (diabetic nephropathy).
- Your fasting blood sugar is less than 11.1 mmol/L and your diabetes medicine has been stable for the last 2 weeks.
- You have not used an SGLT2 inhibitor (a type of diabetes drug) in the past month.
- If you are on dialysis, you must have been on maintenance hemodialysis for more than 3 months, with 3 sessions per week, and your last check showed good dialysis efficiency.
- You have not had more than 2 episodes of low blood sugar in the past month, and no history of diabetic ketoacidosis.
- You are not pregnant or breastfeeding, and you don't have other serious health conditions like recent heart attack or stroke, active infection, or cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medicine called ganagliflozin can slow down kidney damage in people with type 2 diabetes and chronic kidney disease. If you qualify, you may be able to take part in this study to see if it helps protect your kidneys.
This study tests an investigational drug called LC-Z300-01 to see if it can reduce protein in the urine of people with diabetic kidney disease. It aims to protect kidney function and slow down kidney damage.
This trial tests a new oral medication (DWP16001) for people with type 2 diabetes who also have moderate kidney problems. It aims to see if the drug is safe and helps control blood sugar while protecting kidney function.
This trial tests whether a new drug, HTD1801, can protect or improve kidney function in people with type 2 diabetes and chronic kidney disease. It may help slow kidney damage and reduce protein in urine.
This Phase 2 study tests whether adding NAD can improve kidney health in people with diabetes-related kidney disease. It is designed for people with certain urine lab results showing kidney stress, while keeping blood sugar and safety limits within range.
This study tests different doses of an investigational medicine (NNC0519-0130) to see if it can reduce kidney damage in people with chronic kidney disease. It may be an option for you if you have kidney impairment and either have or don't have type 2 diabetes.
Hear when a new Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.